Last reviewed · How we verify
Rescriptor (DELAVIRDINE)
Delavirdine (Rescriptor), marketed by GSK, is a non-nucleoside reverse transcriptase inhibitor (NNRTI) used in the treatment of HIV infection, competing in a crowded market with several other NNRTIs. Its key strength lies in its mechanism of action, which effectively binds to the reverse transcriptase enzyme, thereby preventing HIV replication. The primary risk is the strong competition from off-patent drugs like nevirapine and efavirenz, as well as patent-protected alternatives such as rilpivirine and doravirine, which may limit its market share.
At a glance
| Generic name | DELAVIRDINE |
|---|---|
| Sponsor | GSK |
| Drug class | Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor |
| Target | Histamine H4 receptor |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
| First approval | 1997 |
Approved indications
- Human immunodeficiency virus infection
Common side effects
Drug interactions
- CYP2C19 Substrates
- CYP2C9 Substrates
- CYP2D6 Substrates
- CYP3A4 Substrates
- amprenavir
- erythromycin
- etravirine
- fosamprenavir
- ixabepilone
- lovastatin
- maraviroc
- methylergometrine
Key clinical trials
- Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV (PHASE2,PHASE3)
- Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated Regimen (PHASE2,PHASE3)
- Immunologic and Virologic Consequences of Long-Term Highly Active Antiretroviral Therapy (HAART) in Subjects With Moderately Advanced HIV-1 Disease: A Follow-Up Study to ACTG 315 (PHASE2)
- Randomized, Phase I/II, Dose-Ranging, Open-Label Trial of the Anti-HIV Activity of Delavirdine Mesylate (DLV; U-90,152S) (PHASE1)
- A Study of Several Anti-HIV Drug Combinations in HIV-Infected Patients Who Have Used Indinavir (NA)
- A Phase II Double-Blind Study of Delavirdine Mesylate ( U-90152 ) in Combination With Zidovudine ( AZT ) and/or Didanosine ( ddI ) Versus AZT and ddI Combination Therapy (PHASE2)
- Study to Evaluate Switching From a Regimen of Two Nucleos(t)Ide Reverse Transcriptase Inhibitors (NRTI) Plus a Third Agent to a Fixed Dose Combination (FDC) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), in Virologically-Suppressed, HIV-1 Infected African American Participants (PHASE3)
- CCR5 Inhibitor Treatment Intensification on CD4+ T-cell Recovery (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |